Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca has reported results of the first large real-world evidence study of its kind evaluating the risk of hospitalisation for heart failure and death from any cause in patients with type-2 diabetes (T2D) receiving treatment with a newer class of diabetes medicines, SGLT-2 inhibitors (SGLT-2i).
AB Science pharmaceutical company, specialist in the protein kinase inhibitors (PKIs), said on Monday that it had the first successful phase 3 trial of a tyrosine kinase inhibitor in the treatment of amyotrophic lateral sclerosis (ALS).
Kiadis Pharma, a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, has appointment Jan Feijen as Chief Operations Officer (COO) effective from April 1, 2017.
Bayer AG and Janssen Pharmaceuticals reported results from a study called Einstein Choice on Saturday.
New analysis shows Novartis’ Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes. Novartis said on Saturday the new post-hoc analysis of PARADIGM-HF data demonstrates Entresto lowered levels of HbA1c (a measure of glycemic control) by 0.26% vs. 0.16% for ACE-inhibitor enalapril in heart failure with reduced ejection fraction (HFrEF) patients who also had diabetes.
Nordic Nanovector ASA has begin dosing patients in its Phase 1 Betalutin study, testing a CD37 targeting antibody-radionuclide conjugate, in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are ineligible for stem cell transplantation.
On Thursday, March 16, 2017, the Dow Jones Industrial Average and the S&P 500 edged 0.07% and 0.16% lower, respectively, at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally higher by 0.01%. Five out of nine sectors ended Thursday’s trading session in bullish territories. Taking into consideration yesterday’s market sentiment, Stock-Callers.com assessed the several drugs – generic equities on Friday.
Roche has launched a new instrument for nucleic acid extraction and purification, the MagNA Pure 24 System. The new system offers an extraction solution with on-board primary sample handling for low to medium throughput customers who require high quality nucleic acid extractions, said Roche.
Oxford BioDynamics is one of six consortium partners to examine and address why immune-mediated inflammatory diseases (IMIDs) remit and relapse, with a particular focus on Rheumatoid Arthritis (RA).
AstraZeneca’s subsidiary ZS Pharma has been developing an oral powder as a treatment for high potassium levels in the blood serum, called hyperkalaemia, for which it got a Complete Response Letter (CRL) from the Food and Drug Administration (FDA).